Sucampo to Host 2017 R&D Day on November 16 in New York ROCKVILLE, Md., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will host its 2017 R&D Day...

Sucampo Reports Third Quarter 2017 Financial Results Company Increases 2017 Financial Guidance Based on Strong Performance Year to Date Study Results for VTS-270 for Niemann-Pick Disease Type C1 Published in The Lancet CPP-1X/sulindac Granted...

Sucampo Reports Second Quarter 2017 Financial Results Patent Issued for Pipeline Compound VTS-270 for Niemann-Pick Disease Type C1 Diluted EPS Loss of $3.92 Resulting from $186.6M IP R&D Second Quarter Charge Due to Accounting Treatment of Vtesse...

Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270 ROCKVILLE, Md., June 13, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the U.S. Patent and Trademark Office...

Sucampo Reports First Quarter 2017 Financial Results Continued Revenue Growth Recent Vtesse Acquisition Bolsters Pipeline Company Reiterates 2017 Guidance Company to Host Conference Call Today at 8:30 a.m. EDT ROCKVILLE, Md., May 03, 2017 (GLOBE...